Marked decrease of apolipoprotein A-V in both diabetic and nondiabetic patients with end-stage renal disease.
Apolipoprotein (apo) A-V has been the focus of significant attention as a potential modulator of plasma triglyceride (TG) in spite of its very low plasma concentration. TG levels are frequently elevated in patients with end-stage renal disease (ESRD), which is associated with a high prevalence of cardiovascular disease among them. We measured plasma apo A-V levels in 20 control subjects and 70 patients with diabetic and nondiabetic ESRD to investigate whether low apo A-V levels could be involved in the pathogenesis of the hyper-TG in ESRD. The plasma TG levels were significantly elevated in diabetic patients with ESRD, whereas those in nondiabetic ESRD patients remained similar to those in the controls. High-density lipoprotein cholesterol levels were significantly lower in the patients with ESRD than in the controls, irrespective of the presence of diabetes. Apo A-V levels measured by an enzyme-linked immunosorbent assay were markedly reduced to 40% to 44% of the control levels in both diabetic and nondiabetic patients with ESRD. The apo A-V levels were not correlated with TG in the overall study population, but they were positively correlated with high-density lipoprotein cholesterol. These results suggest that reduced apo A-V levels do not necessarily lead to hyper-TG in ESRD, but we are unable to exclude the possibility that low apo A-V plays a role in raising the TG level in diabetic ESRD.
Hirano
Tsutomu
T
First Department of Internal Medicine, Showa University School of Medicine, Tokyo 142-8666, and Department of Nephrology, Yokohama Daiichi Hospital, Japan. hirano@med.showa-u.ac.jp
Hayashi
Toshiyuki
T
Adachi
Mitsuru
M
Taira
Takayasu
T
Hattori
Hiroaki
H
D000368:Aged; D000072040:Apolipoprotein A-V; D001054:Apolipoproteins A / Q000097:blood*; D016022:Case-Control Studies; D003920:Diabetes Mellitus / Q000097:blood*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged
C437704:APOA5 protein, human; D000072040:Apolipoprotein A-V; D001054:Apolipoproteins A